Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 15/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22871372 | 0.91 | BCAT2 (0.48) | CYP11B2CYP11B1BRD4BRD2BRD3 | |
| SCHEMBL22871332 | 0.86 | BCAT2 (0.48) | CYP11B2BCAT2SRD5A1SRD5A2ALDH1A1 | |
| SCHEMBL14158081 | 0.86 | AOC3 (0.48) | BCAT2SRD5A1SRD5A2ALDH1A1MAPT | |
| SCHEMBL22871290 | 0.85 | CYP11B2 (0.57) | CYP11B2CYP11B1BRD4BRD2BRD3 | |
| SCHEMBL22871288 | 0.83 | CYP11B2 (0.48) | CYP11B2CYP11B1 | |
| SCHEMBL20603199 | 0.80 | BCAT2 (0.49) | BCAT2SRD5A1SRD5A2ALDH1A1MAPT | |
| SCHEMBL22871437 | 0.79 | BCAT2 (0.48) | BCAT2SRD5A1SRD5A2ALDH1A1MAPT | |
| SCHEMBL1180475 | 0.77 | EGFR (0.48) | CYP11B2CYP11B1BCAT2SRD5A1SRD5A2 | |
| SCHEMBL22871253 | 0.76 | BCAT2 (0.45) | BCAT2ALDH1A1MAPT | |
| SCHEMBL22871458 | 0.76 | BCAT2 (0.45) | BCAT2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-10889570-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | CYP11B2 59/4885CYP11B1 93/4885BRD4 202/4885 |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | CYP11B2 59/4885CYP11B1 93/4885BRD4 202/4885 |
| US-11673878-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | CYP11B2 59/4885CYP11B1 93/4885BRD4 202/4885 |
| US-10889570-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | CYP11B2 59/4885CYP11B1 93/4885BRD4 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.